Efficacy of the neurokinin‐1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin‐based chemotherapy

BACKGROUND: Rolapitant, a novel neurokinin‐1 receptor antagonist, provided effective protection against chemotherapy‐induced nausea and vomiting (CINV) in a randomized, double‐blind phase 3 trial of patients receiving moderately emetogenic chemotherapy or an anthracycline and cyclophosphamide regime...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer
Autores principales: Hesketh, Paul J., Schnadig, Ian D., Schwartzberg, Lee S., Modiano, Manuel R., Jordan, Karin, Arora, Sujata, Powers, Dan, Aapro, Matti
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5084806/
https://ncbi.nlm.nih.gov/pubmed/27176138
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30054
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares